All News

This week, the top managed care news included a study questioning the Hospital Readmissions Reduction Program; FDA issuing a warning about do-it-yourself artificial pancreas systems; measles cases reach the highest level since 1994.

New research has identified how bone cells subdue cancer cells that have reached the bone so that the cancer cells remain dormant for decades. The finding may help researchers develop new treatments to prevent or treat metastatic disease and put cancer cells to sleep permanently.

As a precursor to myeloma, smoldering multiple myeloma (MM) currently has no treatment. In fact, the standard of care is observation until the patient starts to present with symptoms. However, according to new research that will be presented at the American Society of Clinical Oncology’s annual meeting in Chicago, Illinois, held May 31 to June 4, early treatment of smoldering MM may delay progression to full-blown disease.

Researchers recently conducted a study in which they trained an artificial intelligence (AI) deep learning tool to detect lung cancer tumors in computed tomography scans. The algorithm's evaluation was then compared with that of 6 radiologists, and the results showed that the AI was more accurate when prior CT imaging was not available.

Senate Majority Leader Mitch McConnell, R-Kentucky, introduced bipartisan legislation that would raise the age to purchase tobacco-related products to 21; the US measles outbreak has surged to 880 cases this year; the FDA will end its Alternative Summary Reporting program after an investigation found that the agency had filed information regarding malfunctions of the Sprint Fidelis heart device in an internal database.

Multifraction radiotherapy is standard to treat pain in patients with bone metastases that are mostly not in their spine, but new research has shown that single-fraction stereotactic body radiotherapy had higher rates of overall pain response and better local disease control.

According to new research published in PNAS, researchers have determined that a molecule that helps blood clot may also play a role in multiple sclerosis (MS) relapses, in addition to discovering a new way of studying the disease in mice that more closely resembles the human form.

A recent study employed the use of a high-throughput ultrasonication-induced amyloid fibrillation assay to amplify and detect α-synuclein aggregates from cerebrospinal fluid (CSF), and investigated the association between seeding activity and clinical indicators. The assay, created by the study investigators and dubbed the HANdai Amyloid Burst Inducer (HANABI), dramatically reduces the time to perform the assay from the estimated 10 days for the shaking-based assays to only several hours.